Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen for Acute B Cell Lymphoblast Leukemia
NCT05088226Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2021
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib, tucidinostat in acute lymphoblastic leukemia (ALL), sponsored by Chinese PLA General Hospital. Started Dec 2021; status: recruiting.
02
Drugs
ruxolitinibtucidinostat
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05088226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05088226.